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Abstract
Background: Emerging attempts have been made to reduce operative trauma and improve cosmetic results of
laparoscopic cholecystectomy. There is a trend towards minimizing the number of incisions such as natural
transluminal endoscopic surgery (NOTES) and single-port laparoscopic cholecystectomy (SPLC). Many retrospective
case series propose excellent cosmesis and reduced pain in SPLC. As the latter has been confirmed in a
randomized controlled trial, patient’s satisfaction on cosmesis is still controversially debated.
Methods/Design: The SPOCC trial is a prospective, multi-center, double blinded, randomized controlled study
comparing SPLC with 4-port conventional laparoscopic cholecystectomy (4PLC) in elective surgery. The hypothesis
and primary objective is that patients undergoing SPLC will have a better outcome in cosmesis and body image
12 weeks after surgery. This primary endpoint is assessed using a validated 8-item multiple choice type
questionnaire on cosmesis and body image. The secondary endpoint has three entities: the quality of life 12 weeks
after surgery assessed by the validated Short-Form-36 Health Survey questionnaire, postoperative pain assessed by
a visual analogue scale and the use of analgesics. Operative time, surgeon’s experience with SPLC and 4PLC, use of
additional ports, conversion to 4PLC or open cholecystectomy, length of stay, costs, time of work as well as intra-
and postoperative complications are further aspects of the secondary endpoint. Patients are randomly assigned
either to SPLC or to 4PLC. Patients as well as treating physicians, nurses and assessors are blinded until the 7th
postoperative day. Sample size calculation performed by estimating a difference of cosmesis of 20% (alpha = 0.05
and beta = 0.90, drop out rate of 10%) resulted in a number of 55 randomized patients per arm.
Discussion: The SPOCC-trial is a prospective, multi-center, double-blind, randomized controlled study to assess
cosmesis and body image after SPLC.
Trial registration: (clinicaltrial.gov): NCT 01278472
Background
Since the first laparoscopic cholecystectomy in 1985, the
laparoscopic approach has emerged as the treatment of
choice for symptomatic gallstone disease [1,2]. Advantages
of laparoscopic compared with open surgery include
improved cosmesis, pain control, shorter convalescence
and the absence of the formation of intra-abdominal
adhesions.
Traditionally laparoscopic cholecystectomy is performed
with four ports. In an attempt to further reduce operative
trauma and improve cosmetic results following laparo-
scopic cholecystectomy, there has been a trend toward
minimizing the number of incisions and ports required.
These new operative techniques are called natural orifice
transluminal endoscopic surgery (NOTES) [3,4] or single-
port laparoscopic surgery (SPLC) [5] and were developed
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in order to improve cosmesis and further reduce the inva-
siveness of conventional laparoscopy [6].
A MEDLINE (Pubmed Central database) search (May
14, 2011) using the keywords ‘cholecystectomy’ and ‘single
port’, ‘single incision’, ‘single site’ or ‘single provided 334
articles. However, there were only two randomized con-
trolled studies which were published. These included a
low number of patients and focused on postoperative pain
[7,8]. Current data show that SPLC is feasible with a low
rate of conversion to 4-Port conventional laparoscopic
cholecystectomy (4PLC) ranging from 2 to 9.3%. The
main reason for conversion was the presence of acute
inflammation [9,10]. Systemic reviews showed an inci-
dence of biliary tract injury between 0.09 and 0.7%. [9-11].
However, high evidence regarding safety of SPLC is
missing.
SPLC is regarded to provide excellent results in cosm-
esis with almost no visible scar [12,13]. Yet, the impor-
tance of the cosmesis has been challenged as patients
also seem to be quite satisfied after 4PLC [14].
Since the available devices for SPLC have been designed
to enable an almost scarless procedure the hypothesis of
cosmesis improvement has to be proven. No previously
published RCT on this topic was designed with the focus
on cosmesis. We therefore designed a double-blinded ran-
domized controlled trial on SPLC versus 4PLC (SPOCC-
trial) evaluating cosmesis and body image as a primary
endpoint.
Methods/Design
Study objectives
The SPOCC trial is a prospective, multi-center, double
blinded, randomized controlled study comparing Single-
Port laparoscopic cholecystectomy with 4-port conven-
tional laparoscopic cholecystectomy in elective surgery for
symptomatic cholecystolithiasis. Patients with an indica-
tion for an elective cholecystectomy are randomized for
either (A) single-port laparoscopic cholecystectomy
(SPLC) or (B) conventional 4-port laparoscopic cholecys-
tectomy (4PLC). The hypothesis of this trial is that
patients undergoing SPLC will have a better outcome in
cosmesis and body image 12 weeks after surgery.
Endpoints
The primary endpoint of the study concerns patient’s
satisfaction with cosmesis and body image 12 weeks after
surgery. This endpoint is assessed using a validated cosm-
esis and body image score (CBIS) that was previously used
in surgery for Crohn’s disease [15] and in donor nephrect-
omy [16]. This score is calculated on an 8-item multiple-
choice type questionnaire (Table 1) ranging between 8 and
48 points.
The secondary endpoint is a combination of several
variables: the quality of life 12 weeks after surgery
assessed by the validated Short-Form-36 Health Survey
questionnaire [17], postoperative pain assessed by a visual
analogue scale daily assessment and the use of analgesics.
Operative time, use of additional ports, conversion to
open cholecystectomy, length of stay, costs, elapsed time
before going back to work as well as intra- and post-
operative complications represent aspects of the second-
ary endpoint. The postoperative complications are
classified according to the Clavien-Dindo system [18].
Power of the study
A clinically relevant improvement of the cosmesis and
body image score (CBIS) [15] is defined as an improve-
ment of 20% of the cosmesis score (8 points). Given the
reported standard deviation of the CBIS between 4-6
Table 1 Cosmesis and Body image questionnaire
consisting of a body image score (items 1 to 5) and a
cosmetic score (items 6 to 8)
1 Are you less satisfied with your body since the operation?
□ 1 = no, not at all
□ 2 = a little bit
□ 3 = quite a bit
□ 4 = yes, extremely
2 Do you think the operation has damaged your body?
□ 1 = no, not at all
□ 2 = a little bit
□ 3 = quite a bit
□ 4 = yes, extremely
3 Do you fell less attractive as a result of your operation?
□ 1 = no, not at all
□ 2 = a little bit
□ 3 = quite a bit
□ 4 = yes, extremely
4 Do you feel less feminine/masculine as a result of your operation?
□ 1 = no, not at all
□ 2 = a little bit
□ 3 = quite a bit
□ 4 = yes, extremely
5 Is it difficult to look at yourself naked?
□ 1 = no, not at all
□ 2 = a little bit
□ 3 = quite a bit
□ 4 = yes, extremely
6 On a scale from 1 to 7, how satisfied are you with your scar(s)?
□ 1 = very unsatisfied
□ 2 = quite unsatisfied
□ 3 = a bit unsatisfied
□ 4 = not unsatisfied/not satisfied
□ 5 = a bit satisfied
□ 6 = quite satisfied
□ 7 = very satisfied
7 On a scale from 1 to 7, how would you describe your scar(s)?
□ 1 = revolting
□ 2 = quite revolting
□ 3 = a bit revolting
□ 4 = not revolting/not beautiful
□ 5 = a bit beautiful
□ 6 = quite beautiful
□ 7 = very beautiful
8 Could you score your own scar(s) on a scale from 1 to 10?
(1 = ugliest scar imaginable, 10 = almost scarless)
Scores from 8 to 48.
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[19] and using (alpha = 0.05 and beta = 0.90), two
groups of 49 patients are needed. This is based on a
two-sided significance level (alpha) of 0.05 and a power
of 0.90. Estimating a 10% dropout rate, which is com-
mon in randomized controlled trials [20], 55 patients
will be randomized per arm.
Inclusion criteria
Inclusion criteria are
- elective cholecystectomy
- 18 years of age
- ability to understand the study purpose (German
language)
- written informed consent
Exclusion criteria
Exclusion criteria are
- pregnant women
- proven or suspected liver cirrhosis
- coagulopathy (platelet count below 50’000/μl)
- double medication on platelet antagonists (acetylsa-
licylic acid and clopidogrel)
- international normalized ratio (INR) below 1.4
- Non-German speakers
- patients who are unable to understand the study
purpose.
- family members of study investigators or employees
of the participating centres
Participating surgeons and clinics
To prevent surgeon bias, the requirements to qualify as a
surgeon are equal in both arms. Since the present study
represents a so-called pragmatic randomised control trial
[21], the study should reflect daily practice for cholecys-
tectomy. Operating surgeons are senior residents, chief
residents, attending surgeons as well as consultant sur-
geons. The operating surgeon will need a minimal experi-
ence of 35 4PLC cholecystectomies,10 SPLC and must
participate in a one-day workshop for SPLC.
Participating centres are the Division of Visceral and
Transplantation Surgery of the University Hospital Zurich
and the Department of Surgery of the Cantonal Hospital
in Winterthur, Switzerland.
Randomization
Patients have to sign an informed consent in the outpa-
tient clinic. Randomization is performed online (internet
randomization module http://www.randomizer.at[22] at
the time of transfer to the operating room.
Double blinding
Patients as well as surgeons, treating physicians and
nurses are blinded until the 7th postoperative day. At the
end of the operation an opaque wound dressing will be
applied at the four port-sites for 4PLC in both treatment
arms. The dressings are occlusive and water-resistant.
The skin will be closed with subcutaneous absorbable
stitches. Additionally the wound will be sealed using
fibrin glue to avoid any blood spots on the dressing. Each
dressing will be marked with a sterile marker so that any
violation of the blinding will be noticed and documented.
Data collection as well as clinical controls of patients is
performed by investigative independent physicians.
Any change of dressings before 7 days postoperatively
are documented.
Data collection and statistics
Informed consent of patients is performed in the outpati-
ent clinic. Single port cholecystectomy is not offered to
patients outside of the study. Data including results of
questionnaires is collected on an internet-based secured
study information platform [23]. The CBIS questionnaire
is filled out at the outpatient clinic preoperatively as well
as on the day of admission, 1 and 12 weeks postopera-
tively. The SF-36 quality of life questionnaire is filled out
preoperatively in the outpatient clinic and 12 weeks post-
operatively. Pain variables are assessed on a daily basis
during hospital stay (Figure 1). Data analysis is performed
in accordance with the intention-to-treat principle.
Groups are compared using an Independent Samples
T-test, Wilcoxon test, or Chi-square test.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and ‘good clinical practice’
guidelines. The principal investigator has completed a
course in ‘good clinical practice’ certified by the Swiss
Agency for Therapeutic Products (Swissmedic). The
independent medical ethics committee of canton Zurich
(Kantonale Ethikkommission Zürich, Switzerland) has
approved the study protocol. This trial was registered at
clinicaltrial.gov on January 14, 2011 (trial number:
NCT01278472).
Surgical technique
Patients are placed in the French position with the sur-
geon between the legs, the cameraman (first assistant) on
the left of the patient, the second assistant (facultative) on
the right, the nurse near the right hand of the surgeon,
and the monitor shoulder level to the patient. The endo-
scopic equipment in terms of optic, monitor, gas supply,
suction device, graspers, monopolar hook and endobag are
equal in both groups. For surgical disinfection of the skin
iodopovidone is used.
Single-Port laparoscopic cholecystectomy (SPLC)
A transumbilical straight 20 to 25 mm skin and fascia
incision is performed (Figure 2). The peritoneum is
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opened and a SILS™ PT12 Port (Covidien Inc., Nor-
walk, California, USA) is introduced. This port obtains
four openings: one for gas insufflation and three that
can accommodate trocars ranging from sizes 5 to
12 mm. The compressibility of the elastic polymer
allows for the access ports to expand and form fit the
space in which it resides as well enabling the ports to
pass through the working channels. The pneumoperito-
neum is maintained at 10-12 mmHg. A 5-mm 45° long
scope (HD EndoEye™, Olympus Europa Holding
GmbH, Hamburg, Germany) is introduced through one
of the openings in the SILS™ Port. The patient is then
placed in an anti-Trendelenburg position. The fundus of
the gallbladder is grasped and the EndoGrab™ (Virtual
Figure 1 Study flowchart.
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Ports Ltd., Caesarea, Israel) internally anchored retrac-
tion system is introduced and placed at the fundus and
the peritoneum parietal. The infundibulum is laterally
retracted using a bending grasper (Endograsp roticula-
tor™, Covidien Inc., Norwalk, California, USA). Subse-
quently good exposure of the triangle of Callot is achieved.
The dissection is done using a monopolar dissection hook.
The cystic artery and duct are first dissected and then
separately clipped with a standard 5 mm clip applicator
(Covidien, Norwalk, California, USA). The gallbladder is
pushed upright and dissected free from the liver by means
of the monopolar hook. Once the gallbladder is free from
the adjacent tissues, the 5 mm trocar is exchanged for a
10 mm trocar which is inserted through the SILS™ access
device. An Endocatch bag (Endocatch Gold, 10 mm; Covi-
dien Inc., Norwalk, California, USA) is inserted and the
gallbladder is extracted. The umbilical fascia is closed
using absorbable Vicryl suture, and the natural scar of the
umbilicus is restored using intracutaneous stitches and
finally covered by dermal glue (Dermabond™; Ethicon
Endosurgery Inc., Smithfield, RI, USA). The SPLC techni-
que which was used, was presented as a video at the 98th
congress of the Swiss Society of Surgery [24].
4-Port laparoscopic cholecystectomy
A 12 mm paraumbilical skin incision is performed, the
fascia and the peritoneum are incised in an open
approach and a 12 mm Hasson-type blunt trocar (Ethi-
con Endosurgery Inc., Smithfield, RI, USA) is introduced.
The pneumoperitoneum is maintained at 10-12 mmHg.
A 10 mm 45° long scope (HD EndoEye™, Olympus
Europa Holding GmbH, Hamburg, Germany) is intro-
duced. Now additional 5 mm trocars are placed under
optical control subxyphoidal on the left side of the
falciforme ligament and in the right lateral upper abdo-
men. These trocars are used as endograspers to retain
the fundus and the infundibulum of the gallbladder. A
further 10 mm reusable trocar is placed in the left middle
abdomen. This trocar is used as dissection instruments,
swabs and the endobag (Figure 3). Optimal exposure of
the triangle of Callot is achieved. The cystic artery and
duct are first dissected and then separately clipped with a
standard 5 mm clip applicator (Covidien, Norwalk, Cali-
fornia, USA). The gallbladder is pushed upright and dis-
sected free from the liver by means of the monopolar
hook. Once the gallbladder is free from the adjacent tis-
sues a standard Endocatch bag (Endocatch Gold, 10 mm;
Covidien, Norwalk, CT, USA) is inserted and the gall-
bladder is extracted. The paraumbilical fascia und the
fascia in the left middle abdomen is closed using absorb-
able Vicryl suture. The skin is closed using intracuta-
neous stitches and covered by dermal glue (Dermabond;
Ethicon Endosurgery, Inc., Smithfield, RI, USA).
Discussion
The prevalence of diagnosed cholecystolithiasis is high:
14.4% in men and 25.3% in women. About half of these
patients are symptomatic and therefore candidates for
cholecystectomy [25]. Laparoscopic cholecystectomy has
become one of the most frequently performed proce-
dures in visceral surgery. Current efforts focus on mini-
mizing the operative trauma and improving cosmesis by
reduction of trocars. On the other hand innovations in
this field represent a significant economic burden.
Hence, the postulated advantages for the patients of
SPLC as well as cost effectiveness need to be evaluated
in prospective randomized studies.
Figure 2 Setting in Single-Port laparoscopic cholecystectomy.
Figure 3 Setting in 4-Port laparoscopic cholecystectomy.
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While many retrospective case series on SPLC are
available [9,10], only two RCTs have been published
showing reduced postoperative pain [8,26].
Currently 9 RCTs are registered in the international
trial database (clinicaltrials.gov) (Table 2). Two trials
have small sample sizes and focus on postoperative
pain (NCT01348620, NCT01094379). The majority of
trials focus on postoperative pain or costs. One trial
with the most extensive sample size (600-patients)
investigates differences in morbidity (Trial of the
European Association of Endoscopic Surgery, EAES,
NCT01104727).
Cosmesis and body image (after 1 month) as a primary
endpoint is considered in only one registered trial
(NCT00904865) while another study focuses on a com-
bined primary endpoint consisting of quality of life
assessed by SF-36, cosmesis and pain (NCT01339325-
trial) (Table 2).
The present SPOCC-trial has two specific advantages,
such as the time point of cosmesis assessment 3 months
after surgery, which represents a reasonable follow-up
time point, using a validated questionnaire and scoring
system [15]. The second strength of the trial design is the
double blinding.
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